NCT00357396View on ClinicalTrials.gov

Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Sarcoma
Interventions
BIOLOGICAL

graft versus host disease prophylaxis/therapy

DRUG

busulfan

DRUG

melphalan

DRUG

thiotepa

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

allogeneic hematopoietic stem cell transplantation

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00357396 - Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors | Biotech Hunter | Biotech Hunter